We Accept Insurance!


Discover the change you’ve been looking for with the latest FDA-approved treatment.

Spravato® is a nasal spray prescribed for treatment-resistant depression. Unlike oral antidepressants, which can take several weeks to months to work, the effects of this medication are typically felt within hours, unlocking a pathway to healing for patients who have not responded to oral antidepressants and/or therapy alone.

A simple, straightforward process
1. Intake & Preparation

At Heading, we offer Spravato® treatment to patients who qualify under their insurance plan and in accordance with FDA’s safety requirements. 


Most insurance companies require at least two prior antidepressant trials, and for patients to be taking an oral antidepressant during the course of treatment.

2. Consultation

Meet with a psychiatrist to determine your treatment protocol. During this 1-hour session, you and a Heading clinician will discuss your history, current symptoms, and treatment options. 


After scheduling your first dosing session, you’ll tour the facility and meet your Heading care team including our psychiatric nurses, and medical assistants.

3. Personalized Treatment

Spravato® appointments are typically scheduled twice weekly for the first month, and once weekly for the second month. You will self-administer the nasal spray under the supervision of your prescriber — then sit back, relax, and allow the effects to unfold. Session are about two hours.


After treatment, if you are also being seen by a Heading Therapist, your therapist can help you process the experience and set intentions for your continued treatment.

The Science Behind Treatment

Spravato® targets the glutamate system in the brain, which plays an important role in healthy brain functioning. Glutamate is a highly abundant neurotransmitter, responsible for facilitating signals between nerve cells.

Research and understanding of this new approach for depression is continuing to deepen. It’s thought to create new connections in the brain, allowing for behavioral and cognitive changes to occur more readily and rapidly in patients with treatment-resistant depression. Clinical trials have shown a 69% response rate and 52% remission rate in patients treated with Spravato® with minimal side effects. 

Begin your journey

Interested in learning more? 

We offer two ways to get started:

  1. Get referred by your doctor or therapist.

    Discuss our services with your provider and have them reach out.

  2. Schedule your consultation.

    Our care counselor will reach out to help you schedule your consultation.

Schedule your consultation